anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: An antioxidative and anti-gastric cancer composition using Pholiota nameko and a functional Pholiota nameko Muk(Korean acorn starch jelly) using the same are provided to prevent or treat gastric cancer. CONSTITUTION: An antioxidatvie and anticancer composition contains Pholiota nameko extract having mucopolysaccharide. The Pholiota nameko extract is obtained by mixing Pholiota nameko fruit body and water, grinding, centrifuging, and collecting supernatant. The Pholiota nameko extract is a freeze-dried powder of lower liquid obtained by centrifugation. The composition further contains concentrated pear juice. The functional Pholiota nameko Muk is produced by mixing agar extract to the Pholiota nameko extract having mucopolysaccharide.
This "delayed Pediarix use clinics" cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B.
Bacterial leaf blight is a devastating disease caused by Xanthomonas oryzae pv. oryzae (Xoo) which causes severe crop loss in rice. The molecular mechanism that initiates defense against such pathogens remains unexplored. Reports have suggested crucial role of several miRNAs in regulating immune responses in plants. Argonaute (AGO) proteins have been implicated in imparting immunity against pathogens by using small RNAs as guide molecules. Here, we show that phosphorylation of rice AGO1a by MAP kinases is required for miRNA expression regulation during Xoo infection. AGO1a is induced in response to pathogen infection and is under the control of SA signaling pathway. The pathogen responsive MAP kinases MPK3, MPK4 and MPK6, interact with AGO1a in planta and can phosphorylate the protein in vitro. Overexpression of AGO1a extends disease resistance against Xoo in rice and leads to a higher accumulation of miRNAs. Conversely, overexpression of a non phosphorylatable mutant protein aggravates disease susceptibility and remarkably suppresses the miRNA expression levels. At a molecular level, phosphorylation of AGO1a by MAP kinase is required for increased accumulation of miRNAs during pathogen challenge. Taken together, the data suggests that OsAGO1a is a direct phosphorylation target of MAP kinases and this phosphorylation is crucial for its role in imparting disease resistance.
The method employs a commercially-available blood cell separator comprising a computer-controlled centrifuge (2) having a rotor (24) into which a blood processing bag (6) containing donor blood is placed. Once the blood is collected, the process is performed entirely within the enclosed centrifuge bowl, preferably in situ at the donor collection site. In the first step, the blood is centrifuged to separate the plasma from the cellular components.  After isolation of the red blood cells from other blood components, the red cells are washed with normal saline or other solution. The red blood cells are then lysed by hypotonic shock to separate the red cell membranes (stroma) and the lysate is collected in a sterile container (44), leaving only the stroma in the centrifuge bowl. The final product can be used as raw material for any of the hemoglobin-based oxygen carriers currently being developed as red cell substitutes. All of the steps are performed within a processing container or blood bag (6) in the bowl centrifuge to minimize handling and maintain sterility. A method for preparing a modified hemoglobin solution incorporates the steps for producing stroma-free hemoglobin, then adding pre-measured reagents to react with the solution and filtering the solution.
Calcium channels in a variety of tissues may contain different subunits, including several different γ (gamma) subunits. We report studies regarding structural features of certain gamma subunits, for example the N-terminal first transmembrane domain (TM1) of the subunit γ6. We disclose that certain structural motifs, for example a GxxxG-like structural motif as described herein, can mediate subunit function for calcium channels. A particular peptide motif that has been identified as significant for the ability to mediate a decrease in calcium current is GxxxA. Compositions and methods are disclosed which are useful in modifying calcium regulation in mammalian cells. In various embodiments, calcium current is modified.
Chronic thoracic pain is pain that originates from the cervicothoracic junction and extends to the lower thoracic vertebrae. It is caused by strain in the thoracic spine area, sustained postures of the neck and thoracic region, sitting on the computer for a long time in slouched position, or overuse of the thoracic spine. This study aims to see the effects of the self-mobilization technique of the thoracic spine on pain, range of motion, and function in patients with chronic thoracic spine pain. A Randomized clinical trial will be conducted at Actilife physiotherapy Rehabilitation center, Horizon Hospital Lahore through a convenient sampling technique on patients who will be allocated using simple random sampling through sealed opaque enveloped into Group A and Group B. Group A will be treated with the self-mobilization technique of thoracic spine and Group B will be treated with thoracic stretching exercises at a frequency of 2 sets with 6 repetitions and thrice a week. Outcome measures will be NPRS, Goniometer, and Oswestry disability index for thoracic spine after 6 weeks. Data will be analyzed during SPSS software version 21. After assessing normality of data by Shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.
PROBLEM TO BE SOLVED: To obtain the subject accelerating agent useful for the treatment and prevention of rheumatoid arthritis, spondylosis deformans, etc., caused by a cartilage disturbance by containing a specific oxadiazolyldihydropyridine derivative. SOLUTION: This objective accelerating agent is obtained by containing an oxadiazolyl-1,4-dihydropyridine derivative of formula I [A, B are each N or C; T1 is a lower alkylene or the like; X is a group of formula II: N(R6) (R6 is H, a lower alkyl or the like); Z is N(R7) (R7 is H, a lower alkyl or the like); R1, R5 are each a lower alkyl or the like; R2 is an aryl or the like; R3 is pyridyl or the like; R4 is H, cyano or the like] or its pharmaceutically permissible salts. The accelerating agent is preferably a treating agent of a cartilage disturbance and osteoarthritis. In preparation, preferably a stabilizing agent (e.g.; albumin) is added. The administering amount of the compound of the formula I is 1-100 mg daily by preferably dividing it one to several times.
The signs and symptoms of overdosage are those of hyperthyroidism (see PRECAUTIONS and ADVERSE REACTIONS). In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures have occurred in a child ingesting 18 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

Treatment of Overdosage

Levothyroxine sodium should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur.

Acute Massive Overdosage - This may be a life-threatening emergency, therefore, symptomatic and supportive therapy should be instituted immediately. If not contraindicated (e.g., by seizures, coma, or loss of the gag reflex), the stomach should be emptied by emesis or gastric lavage to decrease gastrointestinal absorption. Activated charcoal or cholestyramine may also be used to decrease absorption. Central and peripheral increased sympathetic activity may be treated by administering β-receptor antagonists, e.g., propranolol, provided there are no medical contraindications to their use. Provide respiratory support as needed; control congestive heart failure and arrhythmia; control fever, hypoglycemia, and fluid loss as necessary. Large doses of antithyroid drugs (e.g., methimazole or propylthiouracil) followed in one to two hours by large doses of iodine may be given to inhibit synthesis and release of thyroid hormones. Glucocorticoids may be given to inhibit the conversion of T4 to T3. Plasmapheresis, charcoal hemoperfusion and exchange transfusion have been reserved for cases in which continued clinical deterioration occurs despite conventional therapy. Because T4 is highly protein bound, very little drug will be removed by dialysis.

Please view the manufacturer's complete drug information at the FDA site:   
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99aebc74-0e34-4ab3-bb59-d9fb2b9a4444
This study consists of screening period, treatment period and postoperative monitoring period and follow-up period. During the screening period (Days -28 to -1), patients whose parent(s)/legal guardian(s) provide informed consent will complete screening procedures to determine eligibility for trial enrollment. Eligible subjects will be admitted to the clinical research center before surgical administration to complete the preoperative examination and determine the surgical plan. Ommaya fluid reservoir capsule implantation will be used in this study (if there were problems with Ommaya implantation, intra-cerebroventricular injection could also be used for drug administration). The day of administration set to be D1. Prophylactic immunosuppressive therapy including Methylprednisolone, Prednisolone and Rapamycin was initiated on D1. Then all the examinations during the 7-day postoperative observation period will be completed based on the evaluation time point specified in the Schedule of Assessments table. Subjects may be discharged 7 days after the infusion, based on Investigator judgment. During the outpatient follow-up period (up to 52 weeks after administration), subjects will return at regularly scheduled intervals for efficacy and safety assessments until the End of Trial. After the End of Trial visit, eligible patients will be asked to participate into the long-term follow up trial.
Purpose: The study aimed to examine the effect of a child-friendly design on the pain and anxiety levels during blood draw in children aged 1-3 years and the satisfaction levels of their parents toward the environment in which they receive health care services. Methods: The nonrandomized study was conducted with 158 children aged 1-3 years and their parents. Data were obtained with the "Personal Information Form," "Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale," "Visual Analog Scale (VAS) Anxiety Scale," and "Parental Satisfaction Scale-VAS." Data were collected from the control group before the design and from the intervention group after the design. Results: During the blood draw, the VAS Anxiety score of the children in the intervention group was 3.17 ± 1.44 and that of the control group was 7.00 ± 2.51 (t = 246.500, p < .001). The FLACC score was 3.94 ± 1.65 in the intervention group and 7.32 ± 2.51 in the control group (t = 915.000, p < .001). The mean satisfaction scores of the parents in the intervention group for the environment where they received health care were 10.00 ± 0.00, and those of the parents in the control group were 4.85 ± 1.68 (test = -11.561, p < .001). Conclusion: The child-friendly design effectively reduced children's pain and anxiety levels during blood draws and increased parents' satisfaction with the environment in which health care was received. Practical Implications: Implementing a child-friendly design in blood collection units is recommended to alleviate the pain and anxiety associated with children's blood draws, thereby enhancing parental satisfaction with the care provided.
PURPOSE:To provide a cosmetic containing a lactic acid fermentation liquid of soya milk as an active component, effective in remedying the pigmentation such as chloasma, bleaching spots, freckles, etc., preventing the oxidation of sebum and beautifying the human skin and safely usable absolutely without damaging the skin. CONSTITUTION:The objective cosmetic contains a lactic acid fermentation liquid of soya milk. The lactic acid fermentation liquid of soya milk remarkably exhibits the melanogenesis suppressing effect and anti-oxidation capability of B16 cell. The lactic bacteria for the fermentation of soya milk is e.g. Streptococcus thermophilus or Streptococcus lactis. The cosmetic can be used in the form of cream, milky lotion, cream pack, etc.
PURPOSE: A method for preparing a cosmetic material containing a snail fermentation is provided to ensure excellent skin absorption rate, antioxidation and whitening effects. CONSTITUTION: A cosmetic composition contains nanofermentation product which is prepared by mixing snail nanoextract and medium, inoculating lactic acid bacterial and fermenting. The lactic acid bacteria are Bifidobacterium longum, Lactobacillus acidophilus, or Lactobacillus plantarum. The cosmetic composition is manufactured in the form of a nutrition cream, massage cream, essence, eye cream, cleansing cream, pack, and spray. A method for manufacturing a cosmetic material containing a snail fermentation comprises: a step of preparing the snail nanoextract(S110); a step of mixing the snail nanoextract with a medium for culturing the lactic acid bacteria(S120); and a step of inoculating the lactic acid bacteria mixture to the medium and fermenting(S130). [Reference numerals] (AA) Start; (BB) End; (S110) Extracting pulverized snail nanopowder by ultrasonic wave and preparing snail nanoextract containing nanoparticles; (S120) Mixing snail nanoextract in a medium for culturing lactic acid bacteria; (S130) Inoculating lactic acid bacteria to the medium and fermenting
Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
662,587. Blood complex antibiotic preparations. BOWER, J. O. July 25, 1949, No. 19502/49. Class 81 (i) A therapeutic agent is prepared by dissolving an antibiotic such as penicillin, streptomycin and aureomycin in a solution of an animal blood complex comprising haemoglobin and disintegrated blood stroma. In a preferred method blood is centrifuged, the plasma removed and the residual blood rapidly cooled in a carbon-dioxide/kerosene bath at -70‹ C. to -90‹ C. so that the blood cells are disintegrated. The product is thawed and penicillin, preferably in aqueous solution, is added aseptically. A dry powder is obtained by freezing to -70‹ C. and removing liquid under vacuum. For injection, the powder is dissolved in water or plasma; for application to wounds the powder may be applied per se, or be formed into a paste with water or plasma. In a modification, the penicillin may be added direct to the hµmoglobinstroma solution without desiccation and may be used as such. In a further modification, whole blood may be disintegrated and penicillin added thereto. Aseptic technique is used throughout, care being taken to avoid atmospheric oxidation. The blood may be citrated or, if taken direct from the animal and deep frozen immediately, it may be non-citrated. For injection the blood must be human, but for external application that of animals such as pigs, dogs, oxen and sheep may be used. The therapeutic agent may be incorporated in ointment bases, e.g. one containing cerate and/or petroleum jelly, zinc peroxide, boric acid and zinc oxide. Specifications 619,489 and 622,274 are referred to.
PURPOSE: To assess the safety and effectiveness of PTPBD for CBD stones in the elderly population.
METHODS: Patients aged 60 years or older, who underwent PTPBD or ERCP for CBD stones between January 2021 and December 2023, were included in this study and divided into either the PTPBD group or the ERCP group based on the procedure they underwent. Baseline characteristics, intraoperative and postoperative outcomes were collected and analyzed using SPSS 25.0.
RESULTS: A total of 145 cases were enrolled in the study. In terms of intraoperative complications, one patient in the ERCP group experienced hemorrhaging, while one patient in the PTPBD group experienced acute pain. However, neither of these patients were in a serious condition and only required observation. Stone removal procedures were successfully conducted in approximately 95% of cases in both the PTPBD and ERCP groups (95.8 and 94.8%, respectively; P > 0.999). ERCP failures were observed in one patient with a previous Billroth II anastomosis and two patients with unconventional anatomy of the esophagus and stomach. There was no statistically significant difference in postoperative complications between the PTPBD group and the ERCP group (P > 0.05). The length of hospital stays did not differ between the PTPBD group and the ERCP group (P = 0.537 > 0.05).
CONCLUSION: PTPBD can be used in patients who have complicated anatomical issues that make the ERCP procedure difficult. In comparison, PTPBD is a similarly safe, effective, and minimally invasive technique for extracting CBD stones in elderly patients.
BACKGROUND: A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines. We intended to study the effect of early AVR (eAVR) in this subset of asymptomatic patients with preserved left ventricle function.
METHODS AND RESULTS: We searched PubMed and Embase for randomised and observational studies comparing the effect of eAVR versus conservative therapy in patients with severe, asymptomatic AS and normal left ventricular function. The primary outcome was all-cause mortality. The secondary outcomes were composite major adverse cardiac events (MACE) (study defined), myocardial infarction (MI), stroke, cardiac death, sudden death, the development of symptoms, heart failure hospitalisations and major bleeding. We used GRADEPro to assess the certainty of the evidence. In the randomised controlled trial (RCT) only analysis, we found no significant difference in all-cause mortality between the early aortic intervention group versus the conservative arm (CA) (incidence rate ratio, IRR (CI): 0.5 (0.2 to 1.1), I2=31%, p=0.09). However, in the overall cohort, we found mortality benefit for eAVR over CA (IRR (CI): 0.4 (0.3 to 0.7), I2=84%, p<0.01). There were significantly lower MACE, cardiac death, sudden death, development of symptoms and heart failure hospitalisations in the eAVR group. We noticed no difference in MI, stroke and major bleeding.
CONCLUSION: We conclude that there is no reduction in all-cause mortality in the eAVR arm in patients with asymptomatic AS with preserved ejection fraction. However, eAVR reduces heart failure related hospitalisations and death or heart failure hospitalisations.
PROSPERO REGISTRATION NUMBER: CRD42022306132.
INTRODUCTION: Olfactory dysfunction (OD) is common among people with cystic fibrosis (PwCF). The Questionnaire of Olfactory Disorders (QOD) is a validated instrument that evaluates olfactory-specific quality-of-life. The QOD minimal clinically important difference (MCID) and factors associated with olfactory improvement after elexacaftor/tezacaftor/ivacaftor have not been determined for PwCF.
METHODS: Prospective observational data were pooled from three studies that enrolled adult PwCF with chronic rhinosinusitis (CRS). QOD scores and disease characteristics were assessed. To evaluate internal consistency and calculate the QOD MCID, Cronbach's alpha and four distribution-based methods were employed. For participants who enrolled prior to elexacaftor/tezacaftor/ivacaftor, QOD scores were obtained at baseline and after elexacaftor/tezacaftor/ivacaftor initiation. Multivariable regression was used to identify factors associated with QOD improvement.
RESULTS: Of 129 PwCF included, 65 had QOD scores before and 3-6 months after starting elexacaftor/tezacaftor/ivacaftor. Mean baseline QOD score was 6.5 ± 7.9. Mean Cronbach's alpha was ≥0.85. The MCID estimates were as follows: Cohen's effect size = 1.6, standard error of measurement = 2.5, ½ baseline standard deviation = 4.0, and minimal detectable change = 6.9. Mean MCID was 3.7. Of those with pre/post elexacaftor/tezacaftor/ivacaftor QOD scores, the mean change in QOD was -1.3 ± 5.4. After elexacaftor/tezacaftor/ivacaftor, QOD improvement surpassed the MCID in 22% of participants (14/65). Worse baseline QOD scores and nasal polyps were associated with improved QOD scores after elexacaftor/tezacaftor/ivacaftor (both p < 0.04).
CONCLUSION: The QOD MCID in PwCF was estimated to be 3.7. Elexacaftor/tezacaftor/ivacaftor led to qualitative but not clinically meaningful improvements in QOD score for most PwCF; PwCF with worse baseline QOD scores and nasal polyps improved in a clinically significant manner.
PURPOSE:To obtain the titled material capable of promoting the formation of stabilized fibrins stable for a long term, by neutralizing a structure, e.g. a fiber assembly or a sponge, made from oxidized cellulose as a material, and immobilizing a specific factor and thrombin, therein. CONSTITUTION:A structure having a shape of a fiber assembly (preferably having 10-30% -CH2OH oxidized into -COOH in the cellulose for improved bioabsorbability), sponge, powder, monofilament, film or microcapsule,. A blood coagulation factor XIII (F XIII) and thrombin are bonded covalently and immobilized in the above-mentioned structure by a method of using a dehydration condensing agent, etc. to give the aimed fibrination promoting material. The resultant material is usable for treating a wound of cut or abrasion, etc., wound surface by a burn or operation wound surface or being an embolic material used for blood vessel obstruction therapy or injection material used for puncture therapy.
PURPOSE: To investigate the association of strabismic angle obtained by simultaneous prism and cover test (SPCT) and prism alternate cover test (PACT) with the final power of Press-On prism used in adults with symptomatic strabismus.
METHODS: The medical records of consecutive patients seen by a single orthoptist at an urban, tertiary care hospital over a 36-month period were reviewed retrospectively. All subjects had been prescribed Press-On prism for diplopia after evaluation with SPCT and PACT measurements at distance fixation. Prism dispensed was chosen by the patient using a trial Press-On prism set.
RESULTS: A total of 244 charts were reviewed. Of these, 108 adult patients had prism dispensed, and 32 had both SPCT and PACT measurements. Mean SPCT measurement was 7Δ (median, 6Δ; range, 3Δ-14Δ); mean PACT, 13Δ (median, 11Δ; range, 8Δ-20Δ). The mean prism power dispensed was 7Δ (median, 6Δ; range, 1Δ-15Δ); this was not significantly different from mean SPCT (P = 0.35). There was a large difference (6Δ) between mean PACT measurements and mean prism dispensed (P < 0.001). At follow-up of 1 year, 21 patients (66%) remained in prism. Nine patients (4%) elected to undergo eye muscle surgery, 7 with horizontal strabismus, 6 of whom had SPCT measurements of >10Δ and PACT measurements of >15Δ.
CONCLUSIONS: Press-On prism power used was more closely tied to the angle of strabismus obtained by SPCT. Overall success rate of Press-On prism was good when the prism power dispensed was close to the SPCT measurement, suggesting that it is reasonable to initiate treatment with a weaker prism, approximating the SPCT measurement, building up only if there are continuing symptoms.